9月24日 - ** 制药商Acadia Pharmaceuticals ACAD.O股价盘前下跌11%至21美元
** 该公司称其治疗一种罕见代谢疾病的实验性疗法未能 (link) 达到后期研究的主要目标
** ACAD正在测试ACP-101疗法，以治疗普拉德-威利综合征遗传疾病患者的食欲亢进症，即强烈和持续的饥饿感。
** 称公司不打算进一步研究该疗法
** 竞争对手Soleno Therapeutics SLNO.O的股价盘前上涨了13.5%。
** 截至收盘，ACAD累计上涨28.6%，SLNO累计上涨26.5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.